Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020

12th October 2020 – Corporate Spotlight | Telix Pharmaceuticals will participate in AusBiotech + Invest 2020

Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased to be sponsoring the “Radiopharmaceuticals drug development: current and future trends” session on Thursday 29th October 2.15 pm – 3.00 pm (AEST).

We have a fantastic line up of speakers including, Dr David Cade, Chief Business Officer at Telix Pharmaceuticals, Professor Rod Hicks, Director of Molecular Imaging and Therapeutic Nuclear Medicine at the Peter MacCallum Cancer Centre, Dr Danielle Meyrick, Head of R&D (Theranostics) and Medical Advisor, Clinical CRO at GenesisCare and Simone Leyden, CEO and Co-Founder at NeuroEndocrine Cancer Australia.

The session will be chaired by Dr Gabriel Liberatore, Group Chief Operating Officer Telix Pharmaceuticals. There will be an opportunity for Q&A following the speaker presentations.

  • Presentation: Radiopharmaceuticals drug development: current and future trends
  • Format: Virtual Conference (registration required)
  • Date/time: 29th October 2020 at 2.15 pm – 3.00 pm (AEST)

To learn more about AusBiotech, including how to register click here.

To view the Conference Draft program please click here.